Alirocumab and Cardiovascular Outcomes after Acute Coronary Syndrome
Open accessThe DOI matches its Crossref record; 29 of the 29 references it cites were found in a registry or an index; 23 of the 25 sources its claims cite were checked for support.
Abstract
Background Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events. We sought to determine whether alirocumab, a human monoclonal antibody to proprotein convertase subtilisin–kexin type 9 (PCSK9), would improve cardiovascular outcomes after an acute coronary syndrome in patients receiving high‐intensity statin therapy. Methods We conducted a multicenter, randomized, double‐blind, placebo‐controlled trial involving 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier, had a low‐density lipoprotein (LDL) cholesterol level of at least 70 mg per deciliter (1.8 mmol per liter), a non‐high‐density lipoprotein cholesterol level of at least 100 mg per deciliter (2.6 mmol per liter), or an apolipoprotein B level of at least 80 mg per deciliter, and were receiving statin therapy at a high‐intensity dose or at the maximum tolerated dose. Patients were randomly assigned to receive alirocumab subcutaneously at a dose of 75 mg (9462 patients) or matching placebo (9462 patients) every 2 weeks. The dose of alirocumab was adjusted under blinded conditions to target an LDL cholesterol level of 25 to 50 mg per deciliter (0.6 to 1.3 mmol per liter). The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization. Results The median duration of follow‐up was 2.8 years. A composite primary end‐point e…
Overview
CoChat Summary
TL;DR
In patients with a recent acute coronary syndrome receiving high-intensity or maximum-tolerated statin therapy, alirocumab reduced the risk of recurrent ischemic cardiovascular events compared with placebo. The benefit was driven mainly by the composite primary end point, with similar adverse-event rates except for more local injection-site reactions.
Key findings
- The primary composite end point occurred in 903 patients (9.5%) in the alirocumab group vs. 1052 patients (11.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.78 to 0.93; P<0.001); the 4-year Kaplan-Meier estimate was 12.5% vs. 14.5%, and 49 patients would need treatment for 4 years to prevent one primary event.
- Death from any cause occurred in 334 patients (3.5%) in the alirocumab group vs. 392 patients (4.1%) in the placebo group (hazard ratio, 0.85; 95% CI, 0.73 to 0.98).
- Absolute benefit was greater among patients with baseline LDL cholesterol ≥100 mg/dL; in that nonprespecified subgroup, 16 patients (95% CI, 11 to 34) would need treatment for 4 years to prevent one primary event (P<0.001 for interaction).
- Adverse events were similar between groups except local injection-site reactions, which occurred in 3.8% of alirocumab patients vs. 2.1% of placebo patients (P<0.001).
Methods
- Multicenter, randomized, double-blind, placebo-controlled trial enrolling 18,924 patients who had an acute coronary syndrome 1 to 12 months earlier and elevated atherogenic lipid levels despite high-intensity or maximum-tolerated statin therapy.
- Patients were randomly assigned 1:1 to subcutaneous alirocumab 75 mg every 2 weeks (9462 patients) or matching placebo (9462 patients), with blinded dose adjustment targeting LDL cholesterol 25 to 50 mg/dL.
- The primary end point was a composite of death from coronary heart disease, nonfatal myocardial infarction, fatal or nonfatal ischemic stroke, or unstable angina requiring hospitalization; median follow-up was 2.8 years, with intention-to-treat Cox proportional-hazards analysis stratified by geographic region.
Limitations
- The paper states that a limitation of all three PCSK9 antibody trials, including this one, is infrequent use of ezetimibe because its cardiovascular efficacy was established after most patients had already been enrolled.
- The paper states that whether safety and efficacy were influenced by the blinded dose-adjustment strategy is unknown, and that neither this trial nor FOURIER can fully predict longer-term safety of PCSK9 monoclonal antibody treatment.
- Evident from the text: median follow-up was 2.8 years, limiting assessment of longer-term outcomes; the baseline LDL cholesterol ≥100 mg/dL subgroup finding was from a nonprespecified analysis.
Model-written summary. Check it against the paper before relying on it.
Integrity signals
Registry
Cites
Statistics
Figures
Verification
Claims the paper makes
15 Valid · 1 Not valid · 3 Not checked · 54 Own results and interpretations
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“These findings have led to the development of monoclonal antibodies to PCSK9 that produce substantial reductions in LDL cholesterol when administered alone or with a statin. 8-12”
What the sources say
- Supportedcites [8] 8. Stein EA, Mellis S, Yancopoulos GD, et al. Effect of a monoclonal antibody to PCSK9 on LDL cholesterol. N Engl J Med 2012; 366: 1108-18. source
The Discussion (page not supplied) states that REGN727 lowered LDL cholesterol both alone and in subjects already receiving atorvastatin. The Lipid and Lipoprotein Response section reports substantial reductions in the atorvastatin-treated groups. (LLM, conf=0.93)
- Could not verifycites [9] 9. Robinson JG, Farnier M, Krempf M, et al. Efficacy and safety of alirocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1489-99. sourceExperimental — accuracy not yet measured
The supplied copy contains repository metadata and a PDF listing, but no passage reporting LDL-cholesterol outcomes (Abstract listing). Searches for PCSK9 antibodies, alirocumab, LDL reduction, and use with or without a statin returned no matching passages. The claim therefore cannot be checked against our copy. (LLM, conf=0.78)
- Supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. source
The Efficacy End Points section reports substantial LDL-cholesterol reductions with the PCSK9 monoclonal antibody evolocumab both in the diet-alone group and in groups receiving atorvastatin. The paper also describes earlier trials of PCSK9 inhibitors that significantly reduced LDL cholesterol. (LLM, conf=0.92)
- Supportedcites [11] 11. Sabatine MS, Giugliano RP, Keech AC, et al. Evolocumab and clinical outcomes in patients with cardiovascular disease. N Engl J Med 2017; 376: 1713-22. source
The Introduction (p. 1714) says PCSK9 monoclonal antibodies effectively lower LDL cholesterol and that evolocumab reduces it by approximately 60%. Its cited studies include both an anti-PCSK9 monotherapy trial and a trial adding evolocumab to statin therapy (References); the Discussion also reports a 59% reduction with statin therapy. (LLM, conf=0.88)
- Supportedcites [12] 12. Sabatine MS, Giugliano RP, Wiviott SD, et al. Efficacy and safety of evolocumab in reducing lipids and cardiovascular events. N Engl J Med 2015; 372: 1500-9. source
The paper describes PCSK9 monoclonal antibodies as very effective at lowering LDL cholesterol. Its End Points table includes evolocumab trials with no background lipid therapy and trials with statins; the Lipid Changes section reports a 61% LDL-cholesterol reduction with evolocumab versus standard therapy at 12 weeks. The reported reduction is pooled, not a separate estimate for each treatment setting. (LLM, conf=0.90)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“Patients who have had an acute coronary syndrome are at high risk for recurrent ischemic cardiovascular events.”
What the sources say
- Partly supportedcites [1] 1. Fox KA, Goodman SG, Klein W, et al. Management of acute coronary syndromes - variations in practice and outcome; findings from the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2002; 23: 1177-89. sourceExperimental — accuracy not yet measured
The Results section (p. 1181) reports in-hospital reinfarction after acute coronary syndrome, supporting a risk of recurrent events during admission. The paper says six-month outcomes were collected (Data collection), but it does not report those results here, so it does not establish a high risk of recurrent events after discharge. (LLM, conf=0.80)
- Partly supportedcites [2] 2. Jernberg T, Hasvold P, Henriksson M, Hjelm H, Thuresson M, Janzon M. Cardiovascular risk in post-myocardial infarction patients: nationwide real world data demonstrate the importance of a longterm perspective. Eur Heart J 2015; 36: 1163-70. sourceExperimental — accuracy not yet measured
The Results report an 18.3% one-year risk of MI, stroke, or cardiovascular death after an index MI, and the Discussion says risk remained high in subsequent years. This supports the claim for patients after MI, but the study does not establish the same risk for all patients after acute coronary syndrome, a broader group. (LLM, conf=0.84)
plainstates an association- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: passes — The paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“Similarly, a recent meta-analysis showed that intensive lowering of LDL cholesterol (primarily with the use of statins) resulted in a mortality benefit that was observed only among patients with a baseline LDL cholesterol level of 100 mg or more per deciliter. 20”
What the sources say
- Supportedcites [20] 20. Navarese EP, Robinson JG, Kowalewski M, et al. Association between baseline LDL-C level and total and cardiovascular mortality after LDL-C lowering: a systematic review and meta-analysis. JAMA 2018; 319: 1566-79. source
The All-Cause Mortality and Cardiovascular Mortality sections report mortality risk reductions with more intensive LDL-C lowering only in trials with baseline LDL-C levels of at least 100 mg/dL. The Study Selection and Patient Population section reports that 26 of the 34 trials used statin monotherapy, supporting “primarily with statins.” The threshold describes trial-level baseline LDL-C, rather than a demonstrated cutoff for individual patients. (LLM, conf=0.94)
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
Every source the paper cites for this claim was checked and supports it.
In the paper
“A limitation of all three trials is the infrequent use of ezetimibe, for which cardiovascular efficacy was established 5 after most of the patients had already been enrolled and the trials were well under way.”
What the sources say
- Supportedcites [5] 5. Cannon CP, Blazing MA, Giugliano RP, et al. Ezetimibe added to statin therapy after acute coronary syndromes. N Engl J Med 2015; 372: 2387-97. source
The citation is attached to the assertion that ezetimibe’s cardiovascular efficacy was established. The Conclusions report improved cardiovascular outcomes when ezetimibe was added to statin therapy, and the Efficacy End Points section reports significantly fewer cardiovascular events. The timing relative to the citing authors’ three trials is their own framing, not a finding attributed to this source. (LLM, conf=0.91)
plain- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Supported
The cited sources support only part of this claim — read each source’s verdict below.
In the paper
“The current trial and the FOURIER trial showed similar improvements in composite cardiovascular outcomes with PCSK9 inhibition among patients who had a baseline LDL cholesterol level of 70 mg or more per deciliter and whose average baseline LDL cholesterol level was approximately 90 mg per deciliter. 10”
What the sources say
- Partly supportedcites [10] 10. Blom DJ, Hala T, Bolognese M, et al. A 52-week placebo-controlled trial of evolocumab in hyperlipidemia. N Engl J Med 2014; 370: 1809-19. sourceExperimental — accuracy not yet measured
Split into 2 atoms — 0 confirmed, 1 partially supported, 0 disputed, 0 misattributed, 1 unverifiable. Expand the claim to see per-atom verdicts.
plainstates a cause- Asserted: passes — The authors put it forward as true.
- Checkable: passes — It can be checked against evidence.
- Load-bearing: unclear — It is unclear whether the paper’s conclusions depend on it.
- Based: passes — The paper gives a reason why it holds.
- Partly supported
24 more claims · 3 with their cited sources checked
Create a free account to see all 73 claims and every source verdict.
- Probably not a substantial claim. 20
- It may state two separate claims as one. 27
- The quote only partly states this claim. 4
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
The source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“the cumulative data from the FOURIER and ODYSSEY OUTCOMES trials suggest that PCSK9 inhibitors effectively lower LDL-C and cardiovascular risk in individuals with CAD regardless of diabetes mellitus status.”
From Clinical management of stable coronary artery disease in patients with type 2 diabetes mellitus: a scientific statement from the American Heart Association (2020) · cites this paper as [126]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“Two RCTs have reported a beneficial effect on clinical endpoints in ASCVD patients without FH [119,120].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“The mAb PCSK9 inhibitors evolocumab and alirocumab lower LDLC levels by ∼60% and, when added to statin therapy, decrease the risk of major vascular events [119].”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“In the FOURIER trial, which included 27 564 patients with atherosclerotic CV disease, the addition of evolocumab to statin therapy (69% high-intensity therapy) resulted in a 15% relative risk reduction of the composite primary endpoint throughout a 2.2 year follow-up.”
From 2019 ESC/EAS guidelines for the management of dyslipidaemias: lipid modification to reduce cardiovascular risk (2019) · cites this paper as [119]
Experimental — accuracy not yet measuredThe source backs part of the claim, not all of it — or backs it for a different population, condition or comparison.
In the citing paper
“However, the best evidence to support lower LDL cholesterol targets in people with diabetes and established cardiovascular disease derives from multiple large randomized trials investigating the benefi ts of adding nonstatin agents to statin therapy.”
From 10. Cardiovascular Disease and Risk Management: Standards of Care in Diabetes—2023 (2023) · cites this paper as [110]
Experimental — accuracy not yet measured
32 more claims about this paper
Create a free account to see every claim other papers make about this one.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
Each contradiction between two passages listed here was confirmed by an independent check.
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
§ Patients, Trial Regimen, and Follow-up
“In China, 613 patients underwent randomization from May 2016 through February 2017.”
§ Statistical Analysis
“In China, 614 patients underwent randomization after random assignment of the main trial cohort had been completed”
Rated minor: it would not touch a result — a value no result rests on, a p-value that stays on the same side of the significance level, or a conflict that is clerical, resolved elsewhere in the paper, or outside its own findings.
In the paper
“| Missing data | 19 (<0.1) | 12 (<0.1) |”
Reported 0.1 · recomputed 0.200803
Citations
Cites
Ibanez, B., James, S., Agewall, S., Antunes, M. J., Bucciarelli-Ducci, C., Bueno, H., Caforio, A. L. P., Crea, F., Goudevenos, J. A., Halvorsen, S., et al. (2018) · European Heart Journal · doi:10.1093/eurheartj/ehx393 · Cited by 9,728
Self-citationRoffi, M., Patrono, C., Collet, J.-P., Mueller, C., Valgimigli, M., Andreotti, F., Bax, J. J., Borger, M. A., Brotons, C., Chew, D. P., et al. (2016) · European Heart Journal · doi:10.1093/eurheartj/ehv320 · Cited by 8,261
Self-citationEvolocumab and Clinical Outcomes in Patients with Cardiovascular Disease
Sabatine, M. S., Giugliano, R. P., Keech, A. C., Honarpour, N., Wiviott, S. D., Murphy, S. A., Kuder, J. F., Wang, H., Liu, T., Wasserman, S. M., et al. (2017) · New England Journal of Medicine · doi:10.1056/nejmoa1615664 · Cited by 6,138
Intensive versus Moderate Lipid Lowering with Statins after Acute Coronary Syndromes
Cannon, C. P., Braunwald, E., McCabe, C. H., Rader, D. J., Rouleau, J. L., Belder, R., Joyal, S. V., Hill, K. A., Pfeffer, M. A., & Skene, A. M. (2004) · New England Journal of Medicine · doi:10.1056/nejmoa040583 · Cited by 4,938
Ezetimibe Added to Statin Therapy after Acute Coronary Syndromes
Cannon, C. P., Blazing, M. A., Giugliano, R. P., McCagg, A., White, J. A., Theroux, P., Darius, H., Lewis, B. S., Ophuis, T. O., Jukema, J. W., et al. (2015) · New England Journal of Medicine · doi:10.1056/nejmoa1410489 · Cited by 4,487
Self-citation2014 AHA/ACC Guideline for the Management of Patients With Non–ST-Elevation Acute Coronary Syndromes
Amsterdam, E. A., Wenger, N. K., Brindis, R. G., Casey, D. E., Ganiats, T. G., Holmes, D. R., Jaffe, A. S., Jneid, H., Kelly, R. F., Kontos, M. C., et al. (2014) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2014.09.017 · Cited by 3,595
Sequence Variations in PCSK9, Low LDL, and Protection against Coronary Heart Disease
Cohen, J. C., Boerwinkle, E., Mosley, T. H., & Hobbs, H. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa054013 · Cited by 3,181
Mutations in PCSK9 cause autosomal dominant hypercholesterolemia
Abifadel, M., Varret, M., Rabès, J.-P., Allard, D., Ouguerram, K., Devillers, M., Cruaud, C., Benjannet, S., Wickham, L., Erlich, D., et al. (2003) · Nature Genetics · doi:10.1038/ng1161 · Cited by 2,985
2013 ACCF/AHA Guideline for the Management of ST-Elevation Myocardial Infarction
O'Gara, P. T., Kushner, F. G., Ascheim, D. D., Casey, D. E., Chung, M. K., de Lemos, J. A., Ettinger, S. M., Fang, J. C., Fesmire, F. M., Franklin, B. A., et al. (2013) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2012.11.019 · Cited by 2,625
Schwartz, G. G. (2001) · JAMA · doi:10.1001/jama.285.13.1711 · Cited by 2,499
Self-citation
Cited by
Items 301–400 of 3,636
JCS/JSCVS 2018 Guideline on Revascularization of Stable Coronary Artery Disease
Nakamura, M., Yaku, H., Ako, J., Arai, H., Asai, T., Chikamori, T., Daida, H., Doi, K., Fukui, T., Ito, T., et al. (2022) · Institutional Repositories DataBase (IRDB) · doi:10.1253/circj.cj-20-1282 · Cited by 70
Effects of Alirocumab on Cardiovascular Events After Coronary Bypass Surgery
Goodman, S. G., Aylward, P. E., Szarek, M. J., Chumburidze, V., Bhatt, D. L., Bittner, V., Díaz, R., Edelberg, J. M., Hanotin, C., Harrington, R. A., et al. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.07.015 · Cited by 76
Self-citationHypobetalipoproteinemia and abetalipoproteinemia: liver disease and cardiovascular disease
Welty, F. K. (2020) · Current Opinion in Lipidology · doi:10.1097/mol.0000000000000663 · Cited by 71
Advancing targeted protein degradation for metabolic diseases therapy
Zhou, Q., Xiao, H., Yang, F., Wang, Y., Li, P., & Zheng, Z. (2022) · Pharmacological Research · doi:10.1016/j.phrs.2022.106627 · Cited by 78
Anti-Inflammatory Effects of Lipid-Lowering Drugs and Supplements—A Narrative Review
Zivkovic, S., Maric, G., Cvetinovic, N., Lepojevic-Stefanovic, D., & Bozic Cvijan, B. (2023) · Nutrients · doi:10.3390/nu15061517 · Cited by 71
Therapeutic Antibodies in Medicine
Sharma, P., Joshi, R. V., Pritchard, R., Xu, K., & Eicher, M. A. (2023) · Molecules · doi:10.3390/molecules28186438 · Cited by 90
“Other antibodies, such as adalimumab, daclizumab, fresolimumab, belimumab, and tocilizumab, some of which are already approved for different medical applications, are under premarketing investigation [132].”
BackgroundPatel, S. B., Wyne, K. L., Afreen, S., Belalcazar, L. M., Bird, M. D., Coles, S., Marrs, J. C., Peng, C. C., Pulipati, V. P., Sultan, S., et al. (2025) · Endocrine Practice · doi:10.1016/j.eprac.2024.09.016 · Cited by 85
Khan, S. U., Rahman, H., Okunrintemi, V., Riaz, H., Khan, M. S., Sattur, S., Kaluski, E., Lincoff, A. M., Martin, S. S., & Blaha, M. J. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.011581 · Cited by 70
“Both studies were published before ODYSSEY OUTCOMES and thus lacked this large data set.(10) To our knowledge, our current study is the largest updated meta-analysis that, in addition to systematically evaluating the association of LDL-C reduction with incident DM, has quantitatively compared the effects of statins an…”
BackgroundResultInfluentialKhan, S. U., Khan, M. U., Valavoor, S., Khan, M. S., Okunrintemi, V., Mamas, M. A., Leucker, T. M., Blaha, M. J., & Michos, E. D. (2020) · European Journal of Preventive Cardiology · doi:10.1177/2047487319871733 · Cited by 67
Shapiro, M. D., Minnier, J., Tavori, H., Kassahun, H., Flower, A., Somaratne, R., & Fazio, S. (2019) · Journal of the American Heart Association · doi:10.1161/jaha.118.010932 · Cited by 70
“Similarly, positive results from the other antibody (alirocumab) large randomized controlled outcome trial were recently published.(3) PCSK9 inhibitors are highly efficacious lipid-lowering drugs, with LDL-C reductions generally ranging from 50% to 60% in 12-week interventional studies.”
ResultDengue virus induces PCSK9 expression to alter antiviral responses and disease outcomes
Gan, E. S., Tan, H. C., Le, D. H. T., Huynh, T. T., Wills, B., Seidah, N. G., Ooi, E. E., & Yacoub, S. (2020) · Journal of Clinical Investigation · doi:10.1172/jci137536 · Cited by 70
“Two anti-PCSK9 mAbs, alirocumab (Praluent, Sanofi/Regeneron Pharmaceuticals) (34, 44) and evolucumab (Repatha, Amgen) (45, 46), have been licensed as treatments to lower plasma cholesterol.”
BackgroundAntibody-Based Therapeutics for Atherosclerosis and Cardiovascular Diseases
Ji, E., & Lee, S. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22115770 · Cited by 86
“From 1315 sites, the ODYSSEY trial enrolled 18,924 patients diagnosed with acute coronary syndrome (ACS) within 12 months prior to study inclusion [55].”
Tamargo, J. L., Kaski, J. C., Kimura, T., Barton, J. C., Yamamoto, K., Komiyama, M., Drexel, H., Lewis, B. S., Agewall, S., & Hasegawa, K. (2022) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvac040 · Cited by 75
Guidance for the diagnosis and treatment of hypolipidemia disorders
Bredefeld, C., Hussain, M. M., Averna, M. R., Black, D. D., Brin, M. F., Burnett, J. R., Charrière, S., Cuerq, C., Davidson, N. O., Deckelbaum, R. J., et al. (2022) · Journal of clinical lipidology · doi:10.1016/j.jacl.2022.08.009 · Cited by 79
Валерьевич, А. О., HARUTYUNYAN, G., Duplyakov, D. V., Константинова, Е. В., Konstantinova, N. N., Shakhnovich, R. M., Yavelov, I. S., Yakovlev, A. N., Sa, A., Alekyan, B. G., et al. (2025) · Russian Journal of Cardiology · doi:10.15829/1560-4071-2025-6306 · Cited by 100
Barale, C., Bonomo, K., Frascaroli, C., Morotti, A., Guerrasio, A., Cavalot, F. L., & Russo, I. (2019) · Nutrition Metabolism and Cardiovascular Diseases · doi:10.1016/j.numecd.2019.09.012 · Cited by 74
Vijan, S. S. (2019) · Annals of Internal Medicine · doi:10.7326/aitc201911050 · Cited by 78
Management of dyslipidemia in adult solid organ transplant recipients
Warden, B. A., & Duell, P. B. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.01.011 · Cited by 79
Masana, L., Zamora, A., Plana, N., Comas‐Cufí, M., García-Gil, M., Martí‐Lluch, R., Ponjoan, A., Alves‐Cabratosa, L., Elosúa, R., Marrugat, J., et al. (2019) · Journal of Clinical Medicine · doi:10.3390/jcm8071080 · Cited by 76
Global Trends in the Epidemiology and Management of Dyslipidemia
Liu, T., Zhao, D., & Qi, Y. (2022) · Journal of Clinical Medicine · doi:10.3390/jcm11216377 · Cited by 62
Ray, K. K., Vallejo-Vaz, A. J., Ginsberg, H. N., Davidson, M. H., Louie, M. J., Bujas-Bobanovic, M., Minini, P., Eckel, R. H., & Cannon, C. P. (2019) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2019.06.896 · Cited by 69
From Early Pharmacology to Recent Pharmacology Interventions in Acute Coronary Syndromes
Szummer, K. E., Jernberg, T., & Wallentin, L. C. (2019) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2019.03.531 · Cited by 77
Wang, X., Wen, D., Chen, Y., Ma, L., & You, C. (2022) · Cardiovascular Diabetology · doi:10.1186/s12933-022-01542-4 · Cited by 67
Cesaro, A., Bianconi, V., Gragnano, F., Moscarella, E., Fimiani, F., Monda, E., Scudiero, O., Limongelli, G., Pirro, M., & Calabrò, P. (2020) · BioFactors · doi:10.1002/biof.1619 · Cited by 74
“7%, which was paralleled by a 15% reduction in the incidence of major adverse cardiovascular events, during a 48-month follow-up.(54) Twenty-two studies enrolling about 35,000 patients have evaluated the efficacy and safety of evolocumab.”
BackgroundWilleit, P., Yeang, C., Moriarty, P. M., Tschiderer, L., Varvel, S. A., McConnell, J. P., & Tsimikas, S. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.119.016318 · Cited by 71
“…of benefit from “LDL-C” lowering agents, particularly in patients with elevated lipoprotein(a), which may represent up to a third of patients in the population and in recent clinical trials 36,37 who are more likely to have a true LDL-C that is lower than their LDL-C laboratory measurement.”
Advances in biological therapies for dyslipidemias and atherosclerosis
Valanti, E.-K., Dalakoura-Karagkouni, K., Siasos, G., Kardassis, D., Eliopoulos, A. G., & Sanoudou, D. (2020) · Metabolism · doi:10.1016/j.metabol.2020.154461 · Cited by 72
How low is safe? The frontier of very low (<30 mg/dL) LDL cholesterol
Karagiannis, A. D., Mehta, A., Dhindsa, D. S., Virani, S. S., Orringer, C. E., Blumenthal, R. S., Stone, N. J., & Sperling, L. S. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1080 · Cited by 81
“2158 A.D. Karagiannis et al. D ow nloaded from https://academ ic.oup.com /eurheartj/article/42/22/2154/6104339 by guest on 11 July 2021 .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. .. ..…”
BackgroundMethodInfluentialNicholls, S. J., Nissen, S. E., Prati, F., Windecker, S., Kataoka, Y., Puri, R., Hucko, T., Kassahun, H., Liao, J., Somaratne, R. M., et al. (2021) · Cardiovascular Diagnosis and Therapy · doi:10.21037/cdt-20-684 · Cited by 65
“Two large outcomes trials have demonstrated that lowering LDL-C to much lower levels than previously observed reduced cardiovascular events in patients with either stable atherosclerotic cardiovascular disease (23) or in those with an ACS in the prior 4–52 weeks (24).”
BackgroundProprotein convertase subtilisin/kexin type 9 (PCSK9): A potential multifaceted player in cancer
Bhattacharya, A., Chowdhury, A., Chaudhury, K., & Shukla, P. C. (2021) · Biochimica et Biophysica Acta (BBA) - Reviews on Cancer · doi:10.1016/j.bbcan.2021.188581 · Cited by 67
Kraler, S., Libby, P., Evans, P. C., Akhmedov, A., Schmiady, M. O., Reinehr, M., Camici, G. G., & Lüscher, T. F. (2021) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.121.316256 · Cited by 65
Emerging Non-statin Treatment Options for Lowering Low-Density Lipoprotein Cholesterol
Bardolia, C., Amin, N. S., & Turgeon, J. (2021) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2021.789931 · Cited by 74
“The PCSK9 protein has been associated with various inflammatory markers including white blood cells, C-reactive protein, and fibrinogen in individuals with ACS and coronary artery disease (53).”
BackgroundInfluentialLipid-lowering in diabetes: An update
Chait, A., Eckel, R. H., Vrablík, M., & Zambon, A. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.117313 · Cited by 81
Grundy, S. M., & Stone, N. J. (2019) · JAMA Cardiology · doi:10.1001/jamacardio.2019.0777 · Cited by 67
Inclisiran: a novel agent for lowering apolipoprotein B–containing lipoproteins
Warden, B. A., & Duell, P. B. (2021) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000001053 · Cited by 62
Escobar, C., Anguita, M. P., Arrarte, V., Barrios, V., Cequier, A. R., Cosín-Sales, J., Egocheaga, I., de Sá, E. L., Masana, L., Pallarés‐Carratalá, V., et al. (2019) · Revista Española de Cardiología · doi:10.1016/j.recesp.2019.07.024 · Cited by 70
Pouwer, M. G., Pieterman, E. J., Worms, N., Keijzer, N., Jukema, J. W., Gromada, J., Gusarova, V., & Princen, H. M. G. (2020) · Journal of Lipid Research · doi:10.1194/jlr.ra119000419 · Cited by 66
Self-citationWilkinson, M. J., Lepor, N. E., & Michos, E. D. (2023) · Journal of the American Heart Association · doi:10.1161/jaha.122.028892 · Cited by 77
Cost-Effectiveness of Alirocumab
Kazi, D. S., Penko, J. M., Coxson, P. G., Guzman, D., Wei, P. C., & Bibbins-Domingo, K. B. (2018) · Annals of Internal Medicine · doi:10.7326/m18-1776 · Cited by 67
Feng, Q., Wei, W., Chaugai, S., Leon, B. G. C., Mosley, J. D., Leon, D. A. C., Jiang, L., Ihegword, A., Shaffer, C. M., Linton, M. F., et al. (2019) · JAMA Network Open · doi:10.1001/jamanetworkopen.2018.7223 · Cited by 62
The Potential of Probiotics in the Prevention and Treatment of Atherosclerosis
O’Morain, V. L., & Ramji, D. P. (2019) · Molecular Nutrition & Food Research · doi:10.1002/mnfr.201900797 · Cited by 73
Effects of alirocumab on types of myocardial infarction: insights from the ODYSSEY OUTCOMES trial
White, H. D., Steg, P. G., Szarek, M. J., Bhatt, D. L., Bittner, V., Díaz, R., Edelberg, J. M., Ērglis, A., Goodman, S. G., Hanotin, C., et al. (2019) · European Heart Journal · doi:10.1093/eurheartj/ehz299 · Cited by 72
Self-citationPierce, J. B., & Feinberg, M. W. (2020) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.120.314222 · Cited by 68
Targeting Inflammation to Reduce Residual Cardiovascular Risk
Ajala, O. N., & Everett, B. M. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00883-3 · Cited by 65
Lipid Management in Patients Presenting With Acute Coronary Syndromes: A Review
Claessen, B. E. P. M., Guedeney, P., Gibson, C. M., Angiolillo, D. J., Cao, D., Lepor, N. E., & Mehran, R. (2020) · Journal of the American Heart Association · doi:10.1161/jaha.120.018897 · Cited by 71
Návar, A. M., Kolkailah, A. A., Gupta, A., Gillard, K. K., Israel, M. K., Wang, Y., & Peterson, E. D. (2023) · Circulation Cardiovascular Quality and Outcomes · doi:10.1161/circoutcomes.122.009787 · Cited by 69
Tralhão, A., & Póvoa, P. M. S. R. (2020) · Journal of Clinical Medicine · doi:10.3390/jcm9020414 · Cited by 73
Novel emerging therapies in atherosclerosis targeting lipid metabolism
Gupta, M., Blumenthal, C., Chatterjee, S., Bandyopadhyay, D., Jain, V., Lavie, C. J., Virani, S. S., Ray, K. K., Aronow, W. S., & Ghosh, R. K. (2020) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2020.1764937 · Cited by 74
“controlled trials including the FOURIER trial and ODYSSEY Outcomes trial, respectively [15,16].”
MethodHandelsman, Y., Anderson, J. E., Bakris, G. L., Ballantyne, C. M., Beckman, J. A., Bhatt, D. L., Bloomgarden, Z. T., Bozkurt, B., Budoff, M. J., Butler, J., et al. (2022) · Journal of Diabetes and its Complications · doi:10.1016/j.jdiacomp.2021.108101 · Cited by 64
“67–69 All patients at elevated ASCVD risk should receive a statin at the maximally tolerated dose unless there is a contraindication.”
Self-citationFarmakis, I. T., Doundoulakis, I., Pagiantza, A., Zafeiropoulos, S., Antza, C., Karvounis, H. I., & Giannakoulas, G. A. (2020) · Journal of Cardiovascular Pharmacology · doi:10.1097/fjc.0000000000000963 · Cited by 65
Lipoproteins in chronic kidney disease: from bench to bedside
Speer, T., Ridker, P. M., von Eckardstein, A., Schunk, S. J., & Fliser, D. (2020) · European Heart Journal · doi:10.1093/eurheartj/ehaa1050 · Cited by 69
Abdul‐Rahman, T., Lizano-Jubert, I., Garg, N., Talukder, S., López, P. P., Awuah, W. A., Shah, R. M., Chambergo, D., Cantu‐Herrera, E., Farooqi, M., et al. (2023) · Progress in Cardiovascular Diseases · doi:10.1016/j.pcad.2023.06.002 · Cited by 66
Ballantyne, C. M., Gellis, L., Tardif, J.-C., Banka, P., Navar, A. M., Asprusten, E. A., Scott, R., Stroes, E. S. G., Froman, S., Mendizabal, G., et al. (2026) · JAMA · doi:10.1001/jama.2025.20620 · Cited by 68
Nishikido, T., & Ray, K. K. (2019) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2018.00199 · Cited by 70
“The ODYSSEY OUTCOME trial enrolled 18,924 patients who had experienced a recent acute coronary syndrome and with elevated LDL-C levels despite high-intensity statin therapy (57).”
Effects of immunization against PCSK9 in an experimental model of breast cancer
Momtazi‐Borojeni, A. A., Nik, M. E., Jaafari, M. R., Banach, M., & Sahebkar, A. (2019) · Archives of Medical Science · doi:10.5114/aoms.2019.84734 · Cited by 67
Guedeney, P., Sorrentino, S., Giustino, G., Chapelle, C., Laporte, S., Claessen, B. E. P. M., Ollier, É., Camaj, A., Kalkman, D. N., Vogel, B., et al. (2020) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvaa024 · Cited by 67
Cost-Effectiveness of Alirocumab in Patients With Acute Coronary Syndromes
Bhatt, D. L., Briggs, A. H., Reed, S. D., Annemans, L., Szarek, M. J., Bittner, V., Díaz, R., Goodman, S. G., Harrington, R. A., Higuchi, K., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.03.029 · Cited by 67
Self-citationNew Pharmacological Approaches to Target PCSK9
Catapano, A. L., Pirillo, A., & Norata, G. D. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00847-7 · Cited by 66
“A potential issue related to monoclonal antibodies is their immunogenicity; antidrug antibodies to evolocumab and alirocumab, both fully human monoclonal antibodies, were observed in a very small percentage of patients [26••, 36, 37], and did not influence drug efficacy [38]. Of note, bococizumab, a humanized monoclon…”
BackgroundHooper, A. J., Tang, X. L., & Burnett, J. R. (2024) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2024.2369747 · Cited by 75
“The ODYSSEY OUTCOMES trial showed comparably low rates of MACE among patients treated with alirocumab, and LDL-cholesterol similarly reduced by ~60% from baseline [10].”
New Perspectives on Atherogenic Dyslipidaemia and Cardiovascular Disease
Lorenzatti, A. J., & Toth, P. P. (2020) · European Cardiology Review · doi:10.15420/ecr.2019.06 · Cited by 72
Atherosclerosis and inflammation. New therapeutic approaches
Pedro‐Botet, J., Climent, E., & Benaiges, D. (2020) · Medicina Clínica (English Edition) · doi:10.1016/j.medcle.2020.04.020 · Cited by 82
Sud, M. K., Han, L., Koh, M., Abdel-Qadir, H. M., Austin, P. C., Farkouh, M. E., Godoy, L. C., Lawler, P. R., Udell, J. A., Wijeysundera, H. C., et al. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.07.033 · Cited by 72
Dyslipidemia in nonalcoholic fatty liver disease
Amor, A. J., & Perea, V. (2019) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000464 · Cited by 69
Triglycerides and residual risk
Vallejo‐Vaz, A. J., Corral, P., Schreier, L. E., & Ray, K. K. (2020) · Current Opinion in Endocrinology Diabetes and Obesity · doi:10.1097/med.0000000000000530 · Cited by 65
Lipid lowering therapy in cardiovascular disease: From myth to molecular reality
Mourikis, P., Zako, S., Dannenberg, L., Nia, A. M., Heinen, Y., Busch, L., Richter, H., Hohlfeld, T., Zeus, T., Kelm, M., et al. (2020) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2020.107592 · Cited by 62
Cholesterol-Lowering Agents: PCSK9 Inhibitors Today and Tomorrow
Rosenson, R. S., Hegele, R. A., & Köenig, W. (2019) · Circulation Research · doi:10.1161/circresaha.118.313238 · Cited by 63
Kanoni, S., Graham, S. E., Wang, Y., Surakka, I. L., Ramdas, S., Zhu, X., Clarke, S. L., Bhatti, K. F., Vedantam, S., Winkler, T. W., et al. (2022) · Genome biology · doi:10.1186/s13059-022-02837-1 · Cited by 78
Qamar, A., Giugliano, R. P., KEECH, A. C., Kuder, J., Murphy, S. A., Kurtz, C. E., Wasserman, S. M., Sever, P. S., Pedersen, T. R., & Sabatine, M. S. (2018) · JAMA Cardiology · doi:10.1001/jamacardio.2018.4178 · Cited by 63
“Cholesterol-Years” for ASCVD Risk Prediction and Treatment
Shapiro, M. D., & Bhatt, D. L. (2020) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2020.08.004 · Cited by 73
Self-citationSzarek, M. J., Reijnders, E., Jukema, J. W., Bhatt, D. L., Bittner, V., Díaz, R., Fazio, S., Garon, G., Goodman, S. G., Harrington, R. A., et al. (2023) · Circulation · doi:10.1161/circulationaha.123.066398 · Cited by 65
Self-citationLeósdóttir, M., Schubert, J. R., Brandts, J., Gustafsson, S., Cars, T., Sundström, J., Jernberg, T., Ray, K. K., & Hagström, E. (2025) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2025.02.007 · Cited by 72
Cholesterol Lowering and Prevention of Stroke: An Overview
Hackam, D. G., & Hegele, R. A. (2019) · Stroke · doi:10.1161/strokeaha.118.023167 · Cited by 72
Balla, S., Ekpo, E., Wilemon, K. A., Knowles, J. W., & Rodríguez, F. (2020) · Current Atherosclerosis Reports · doi:10.1007/s11883-020-00881-5 · Cited by 65
Monami, M., Sesti, G., & Mannucci, E. (2019) · Diabetes, Obesity and Metabolism · doi:10.1111/dom.13599 · Cited by 58
Gaba, P., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Juliano, R. A., Jiao, L., Doyle, R. T., et al. (2022) · Journal of the American College of Cardiology · doi:10.1016/j.jacc.2022.02.035 · Cited by 61
Self-citationNovel therapeutic targets and emerging treatments for atherosclerotic cardiovascular disease
Zheng, W. C., Chan, W., Dart, A. M., & Shaw, J. A. (2023) · European Heart Journal - Cardiovascular Pharmacotherapy · doi:10.1093/ehjcvp/pvad074 · Cited by 68
Schnell, O., Standl, E., Catrinoiu, D., Genovese, S., Lalic, N. M., Skra, J., Valensi, P. E., & Ceriello, A. (2016) · Cardiovascular Diabetology · doi:10.1186/s12933-016-0357-x · Cited by 60
Amarenco, P., Kim, J. S., Labreuche, J., Charles, H., Giroud, M., Lee, B., Mahagne, M., Nighoghossian, N., Steg, P. G., Vicaut, É., et al. (2020) · Stroke · doi:10.1161/strokeaha.119.028718 · Cited by 71
Self-citationDaniels, S. R., Caprio, S., Chaudhari, U., Manvelian, G. Z., Baccara‐Dinet, M. T., Brunet, A., Scemama, M., Loizeau, V., & Bruckert, É. (2020) · Journal of clinical lipidology · doi:10.1016/j.jacl.2020.03.001 · Cited by 61
Therapeutic RNA-silencing oligonucleotides in metabolic diseases
Goga, A., & Stoffel, M. (2022) · Nature Reviews Drug Discovery · doi:10.1038/s41573-022-00407-5 · Cited by 58
Grześk, G., Dorota, B., Wołowiec, Ł., Wołowiec, A., Osiak, J., Kozakiewicz, M., & Banach, J. (2022) · Biomedicine & Pharmacotherapy · doi:10.1016/j.biopha.2022.113957 · Cited by 58
Revisiting secondary prevention in coronary heart disease
Sigamani, A., & Gupta, R. (2022) · Indian Heart Journal · doi:10.1016/j.ihj.2022.11.011 · Cited by 87
Beyond statins: New pharmacological targets to decrease LDL-cholesterol and cardiovascular events
Raschi, E., Casula, M., Cicero, A. F. G., Corsini, A., Borghi, C., & Catapano, A. L. (2023) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2023.108507 · Cited by 71
Sarraju, A., Brennan, D. M., Hayden, K., Stronczek, A., Goldberg, A. C., Michos, E. D., McGuire, D. K., Mason, D., Tercek, G., Nicholls, S. J., et al. (2025) · The Lancet · doi:10.1016/s0140-6736(25)00721-4 · Cited by 66
Goldberg, R. B., Stone, N. J., & Grundy, S. M. (2020) · Diabetes Care · doi:10.2337/dci19-0036 · Cited by 58
Diaz, R., Li, Q. H., Bhatt, D. L., Bittner, V. A., Baccara-Dinet, M. T., Goodman, S. G., Jukema, J. W., Kimura, T., Parkhomenko, A., Pordy, R., et al. (2021) · European Journal of Preventive Cardiology · doi:10.1177/2047487320941987 · Cited by 47
Self-citationPeterson, B. E., Bhatt, D. L., Steg, P. G., Miller, M., Brinton, E. A., Jacobson, T. A., Ketchum, S. B., Juliano, R. A., Jiao, L., Doyle, R. T., et al. (2021) · Circulation · doi:10.1161/circulationaha.120.050276 · Cited by 57
Self-citationGerhardt, T., Seppelt, C., Abdelwahed, Y. S., Meteva, D., Wolfram, C., Stapmanns, P., Erbay, A., Zanders, L., Nelles, G., Musfeld, J., et al. (2023) · European Heart Journal · doi:10.1093/eurheartj/ehad334 · Cited by 68
Advancements in risk stratification and management strategies in primary cardiovascular prevention
Barkas, F., Şener, Y. Z., Golforoush, P. A., Kheirkhah, A., Rodríguez‐Sánchez, E., Novák, J., Apellániz-Ruiz, M., Akyea, R. K., Bianconi, V., Ceasovschih, A., et al. (2024) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2024.117579 · Cited by 64
Schubert, J., Leosdottir, M., Lindahl, B., Westerbergh, J., Melhus, H., Modica, A., Cater, N., Brinck, J., Ray, K. K., & Hagström, E. (2024) · European Heart Journal · doi:10.1093/eurheartj/ehae576 · Cited by 57
“9,27,28 A non–HDL-C level of 2.2 mmol/L is stated as the corresponding level to an LDL-C of 1.4 mmol/L in the same guidelines.”
InfluentialGrundy, S. M., & Stone, N. J. (2019) · Annals of Internal Medicine · doi:10.7326/m19-0365 · Cited by 66
Mach, F., Visseren, F. L. J., Cater, N. B., Salhi, N., Soronen, J., Ray, K. K., Delgado, V., Jukema, J. W., Laufs, U., Zamorano, J.-L., et al. (2024) · Journal of Clinical Lipidology · doi:10.1016/j.jacl.2024.07.001 · Cited by 57
Self-citationA Placebo-Controlled Trial of the Oral PCSK9 Inhibitor Enlicitide
Navar, A. M., Mikhailova, E., Catapano, A. L., Banka, P., Blom, D. J., Cadena, A., Kourpanidis, S., Lepor, N. E., Tsukamoto, K., Mendizabal, G., et al. (2026) · New England Journal of Medicine · doi:10.1056/nejmoa2511002 · Cited by 57
Robinson, J. G., Jayanna, M. B., Brown, A. S., Aspry, K. E., Orringer, C. E., Gill, E. A., Goldberg, A. C., Jones, L. K., Maki, K. C., Dixon, D. L., et al. (2019) · Journal of clinical lipidology · doi:10.1016/j.jacl.2019.05.005 · Cited by 58
Toth, P. P., Bray, S., Villa, G., Palagashvili, T., Sattar, N., Stroes, E. S. G., & Worth, G. M. (2022) · Journal of the American Heart Association · doi:10.1161/jaha.122.025551 · Cited by 56
Valensi, P. E., Henry, P., Boccara, F., Cosson, E., Prévost, G., Emmerich, J., Ernande, L., Marcadet, D. M., Mousseaux, É., Rouzet, F., et al. (2020) · Diabetes & Metabolism · doi:10.1016/j.diabet.2020.08.002 · Cited by 62
Ray, K. K., Nicholls, S. J., Ginsberg, H. N., Johansson, J. O., Kalantar‐Zadeh, K., Kulikowski, E., Toth, P. P., Wong, N. C. W., Cummings, J. L., Sweeney, M., et al. (2019) · American Heart Journal · doi:10.1016/j.ahj.2019.08.001 · Cited by 60
Self-citationOta, H., Omori, H., Kawasaki, M., Hirakawa, A., & Matsuo, H. (2021) · European Heart Journal - Cardiovascular Imaging · doi:10.1093/ehjci/jeab034 · Cited by 56
Ginsberg, H. N., Rosenson, R. S., Hovingh, G. K., Letierce, A., Samuel, R., Poulouin, Y., & Cannon, C. P. (2021) · Journal of Lipid Research · doi:10.1016/j.jlr.2021.100148 · Cited by 60
Gargiulo, P., Basile, C., Cesaro, A., Marzano, F., Buonocore, D., Asile, G., Abbate, V., Vicidomini, F., Paolillo, S., Spaccarotella, C., et al. (2023) · Atherosclerosis · doi:10.1016/j.atherosclerosis.2023.01.001 · Cited by 61
Gargiulo, P., Basile, C., Galasso, G., Bellino, M., D’Elia, D., Patti, G., Bosco, M., Prinetti, M., Andò, G., Campanella, F., et al. (2024) · European Journal of Preventive Cardiology · doi:10.1093/eurjpc/zwae170 · Cited by 59
Metadata
- Authors
- Schwartz, G. G., Steg, P. G., Szarek, M., Bhatt, D. L., Bittner, V. A., Diaz, R., Edelberg, J. M., Goodman, S. G., Hanotin, C., Harrington, R. A., Jukema, J. W., Lecorps, G., Mahaffey, K. W., Moryusef, A., Pordy, R., Quintero, K., Roe, M. T., Sasiela, W. J., Tamby, J.-F., Tricoci, P., White, H. D., & Zeiher, A. M.
- Affiliations
- Inserm (FR)
- From the Division of Cardiology, University of Colorado School of Medicine, Aurora (G.G.S.); Assistance Publique–Hôpitaux de Paris, Hôpital Bichat, Paris Diderot University, Sorbonne Paris Cité, FACT (French Alliance for Cardiovascular Trials), and INSERM Unité 1148 (P.G.S.), and Sanofi (C.H., G.L.) — all in Paris; the National Heart and Lung Institute, Imperial College, Royal Brompton Hospital, London (P.G.S.); the State University of New York Downstate School of Public Health, Brooklyn (M.S.), and...
- State University of New York (US)
- Brigham and Women's Hospital (US)
- St. Michael's Hospital (CA)
- Goethe University Frankfurt (DE)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2018-11-29
- Volume
- 379
- Issue
- 22
- Pages
- 2097-2107
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W2899997727
- Semantic Scholar
- 3bd18f4d47c498a70a737151f3b2a9a1a09050bd
- Cited by
- 3,634
- References
- 22
- Citations by year
- 2026: 452 · 2025: 403 · 2024: 450 · 2023: 446 · 2022: 471 · 2021: 473 · 2020: 481 · 2019: 414 · 2018: 31
- FWCI
- 363.89
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- Research at the University of Copenhagen (University of Copenhagen) (publishedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (publishedVersion)
- SZTE Publicatio Repozitórium (University of Szeged) (acceptedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich) (acceptedVersion, other-oa)
- Leiden Repository (Leiden University) (submittedVersion)
- Lanzhou University Institutional Repository (submittedVersion)
- EUR Research Repository (Erasmus University Rotterdam) (submittedVersion)
- Data Archiving and Networked Services (DANS) (submittedVersion, other-oa)
- HAL (submittedVersion)
- eScholarship (California Digital Library) (submittedVersion)
- Institutional Repositories DataBase (IRDB) (submittedVersion, cc-by-nc-nd)
- IRIS Research product catalog (Sapienza University of Rome) (submittedVersion)
- Lirias (submittedVersion)
- Dspace Repository (Marmara Üniversitesi) (submittedVersion)
- Radboud Repository (Radboud University) (submittedVersion)
- Griffith Research Online (submittedVersion)
- Zurich Open Repository and Archive (University of Zurich) (submittedVersion, other-oa)
- Zurich Open Repository and Archive (University of Zurich)
- Funders
- Sanofi
- Regeneron Pharmaceuticals
- Topics
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Lipoproteins and Cardiovascular Health
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Acute Myocardial Infarction Research
- Health Sciences › Medicine › Cardiology and Cardiovascular Medicine › Antiplatelet Therapy and Cardiovascular Diseases
- Keywords
- alirocumab, PCSK9 inhibitors, acute coronary syndrome, cardiovascular outcomes, LDL cholesterol lowering, high-intensity statin therapy, LDL cholesterol targets, cardiovascular mortality, myocardial infarction, ischemic stroke, unstable angina, apolipoprotein B, non-HDL cholesterol, secondary prevention, cardiovascular risk reduction, LDL-C lowering therapy
- MeSH terms
- Proprotein Convertase 9, PCSK9 Inhibitors, Adult, Aged, Antibodies, Monoclonal, Anticholesteremic Agents, Cardiovascular Diseases, Double-Blind Method, Female, Follow-Up Studies, Humans, Hypercholesterolemia, Cholesterol, LDL, Male, Middle Aged, Acute Coronary Syndrome, Antibodies, Monoclonal, Humanized
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
The claim verdicts this report counts are experimental: their accuracy is not yet measured.
A language model drew the claims from the paper on 2026-10-08, under version 3 of the claim definition (model deepseek-v4.1-flash, prompt extract-v3).
A second model labelled each claim on 2026-10-08 (model jev-1.13-20260917, definition revision gold-guideline-v0.2).
Cited sources are checked with a language model’s help (gpt-6-sol).
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.

